Lori Anne Kunkel, Director at Enliven Therapeutics, Inc. (ELVN), sold 10,000 shares at $49.98 ($505K) on 2026-07-06, disclosed to the SEC on 2026-07-08.
Scheduled sale ($505k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $49.98 | 4,111 | $205K | 40.7% |
| 2 | $50.84 | 5,889 | $299K | 59.3% |
| Total | $50.49 avg | 10,000 | $505K | 100% |
| Filing → |
| LOXO | SELL | 2018-10-03 | $852K | — | Filing → |
| LOXO | SELL | 2018-06-18 | $14.1M | — | Filing → |
| LOXO | SELL | 2018-04-24 | $782K | — | Filing → |